Ceballos-Viro J, López-Picazo JM, Pérez-Gracia JL, Sola JJ, Aisa G, Gil-Bazo I. Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer. World J Gastroenterol 2009; 15(18): 2290-2292 [PMID: 19437574 DOI: 10.3748/wjg.15.2290]
Corresponding Author of This Article
Ignacio Gil-Bazo, MD, PhD, Department of Oncology, Clínica Universidad de Navarra, c/Pío XII 36, 31008 Pamplona (Navarra), Spain. igbazo@unav.es
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. May 14, 2009; 15(18): 2290-2292 Published online May 14, 2009. doi: 10.3748/wjg.15.2290
Fibrosing cholestatic hepatitis following cytotoxic chemotherapy for small-cell lung cancer
Jaime Ceballos-Viro, José M López-Picazo, José L Pérez-Gracia, Jesús J Sola, Gregorio Aisa, Ignacio Gil-Bazo
Jaime Ceballos-Viro, José M López-Picazo, José L Pérez-Gracia, Ignacio Gil-Bazo, Department of Oncology, Clínica Universidad de Navarra, Pio XII 36, 31008 Pamplona, Spain
Jesús J Sola, Gregorio Aisa, Department of Pathology, Clínica Universidad de Navarra, Pio XII 36, 31008 Pamplona, Spain
Author contributions: Ceballos-Viro J performed data gathering and paper writing; López-Picazo JM was responsible for the patient’s treatment, writing of the paper and its supervision; Pérez-Gracia JL performed writing of the paper and its supervision; Sola JJ was responsible for the pathology assessment and graphic material editing; Aisa G contributed to the pathology assessment and graphic material editing; Gil-Bazo I was responsible for writing of the paper and its supervision.
Correspondence to: Ignacio Gil-Bazo, MD, PhD, Department of Oncology, Clínica Universidad de Navarra, c/Pío XII 36, 31008 Pamplona (Navarra), Spain. igbazo@unav.es
Telephone: +34-948-255400
Fax: +34-948-255500
Received: December 12, 2008 Revised: March 23, 2009 Accepted: March 30, 2009 Published online: May 14, 2009
Abstract
Fibrosing cholestatic hepatitis (FCH) is a variant of viral hepatitis reported in hepatitis B virus or hepatitis C virus infected liver, renal or bone transplantation recipients and in leukemia and lymphoma patients after conventional cytotoxic chemotherapy. FCH constitutes a well-described form of fulminant hepatitis having extensive fibrosis and severe cholestasis as its most characteristic pathological findings. Here, we report a case of a 49-year-old patient diagnosed with small-cell lung cancer who developed this condition following conventional chemotherapy-induced immunosuppression. This is the first reported case in the literature of FCH after conventional chemotherapy for a solid tumor. In addition to a detailed report of the case, a physiopathological examination of this potentially life-threatening condition and its treatment options are discussed.
